Recently, the standard of care for metastatic Castration Resistant Prostate Cancer (mCRPC)
has changed considerably. Persistent androgen receptor (AR) signaling has been identified …

Androgen deprivation therapy (ADT), which involves the maximal suppression of circulating
testosterone, underpins the treatment approach to metastatic hormone sensitive prostate …

Background The tumors of many patients with prostate cancer eventually become refractory
to androgen deprivation therapy with progression to metastatic castration-resistant disease …

Androgen deprivation therapy (ADT) is the standard of care for patients with metastatic
prostate cancer (mPC). However, nearly all patients with mPC progress to castration …

Prostate cancer (PC) is the leading cause of cancer and the second leading cause of cancer-
death among men in the Western world. About 10–20% of men with PC present with …

Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR)
signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal …

Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (CRPC), a disease state now recognized to retain …

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial
responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The …

Recent data report that abiraterone acetate, a specific inhibitor of CYP17 that is key to
androgen and estrogen synthesis, improves survival in metastatic castration-resistant …

Background Androgen-targeted therapy and chemotherapy are currently the mainstay of
treatment in metastatic castration resistant prostate cancer (mCRPC). When progression …